Flagship Pioneering unveiled Expedition (also called Expedition Medicines), an AI-driven drug discovery company seeded with $50 million and an early collaboration with Pfizer to target cancer and immune diseases. Flagship’s new vehicle follows its prior successes building AI-focused biotech companies and aims to accelerate discovery using generative chemistry and biology tools. Expedition’s launch underscores continued VC appetite for AI-biotech hybrids that pair computational platforms with deep-pocketed pharma partners. The company will deploy the capital to expand discovery teams, validate outputs preclinically and push lead candidates toward IND-enabling studies.